Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT06693531
Active, not recruiting Observational

A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

NCT06693531 · tracked via the Priya Life Science USA tracker
Sponsor
Regeneron Pharmaceuticals
Phase
Observational
Started
2024-11-22
Last updated
2026-08-12

Condition(s) studied

Eosinophilic Esophagitis (EoE)

Investigational drug(s) / intervention(s)

dupilumab →

dupilumab: No investigational agents will be provided. Dupilumab will be prescribed as per usual clinical practice and will not be provided by the sponsor.

Study summary

This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab).

The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE.

Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward.

Patient questionnaires will measure the following:

* How EoE makes one feel
* EoE signs and/or symptoms, eg, how difficult it is to swallow
* How EoE affects quality-of-life
* How EoE impacts aspects of daily life
* How EoE symptoms have changed throughout the study

Eligibility

Sex
ALL
Min age
1 Year
Max age
—
Healthy volunteers
No
Key Inclusion Criteria: 1. Initiating treatment with DUPIXENT® for EoE according to the USPI 2. Participants aged ≥12 years and caregivers or legal guardians of participants aged \<12 years must be able to understand and complete registry-related questionnaires Key Exclusion Criteria: 1. Patients who have a contraindication to DUPIXENT® according to the USPI 2. Treatment with DUPIXENT® within the 6 months prior to the screening assessment 3. Participation in an ongoing interventional study on or within 6 months of the baseline assessment. Once enrolled in registry, participation is allowed in other ongoing studies (at the discretion of the registry investigator) NOTE: Other protocol defined inclusion/exclusion criteria apply

Primary outcome measure(s)

  • Demographic characteristic of participants who receive dupilumab for EoE: Age — Baseline and up to 3 years after treatment initiation
  • Demographic characteristic of participants who receive dupilumab for EoE: Race — Baseline and up to 3 years after treatment initiation
  • Demographic characteristic of participants who receive dupilumab for EoE: Weight — Baseline and up to 3 years after treatment initiation
  • Demographic characteristic of participants who receive dupilumab for EoE: Height — Baseline and up to 3 years after treatment initiation
  • Disease characteristics of participants who receive dupilumab for EoE: Esophagogastroduodenoscopy (EGD) — Baseline and up to 3 years after treatment initiation
  • Disease characteristics of participants who receive dupilumab for EoE: Dilation/impaction history — Baseline and up to 3 years after treatment initiation
  • Disease characteristics of participants who receive dupilumab for EoE: Dietary interventions — Baseline and up to 3 years after treatment initiation
  • Disease characteristics of participants who receive dupilumab for EoE: Medical history — Baseline and up to 3 years after treatment initiation
  • EoE medication history of participant — Previous 1 year and up to 3 years after treatment initiation
  • Non-EoE medication history of participant — Previous 3 months and up to 3 years after treatment initiation
  • Prior dupilumab exposure history of participant — Baseline and up to 3 years after treatment initiation

Trial sites (54)

FacilityCityRegionStatus
Phoenix Childrens Hospital Phoenix Arizona
Arizona Digestive Health/GI Alliance Sun City Arizona
Arkansas Childrens Hospital Little Rock Arkansas
Scripps Clinic La Jolla California
University of California Los Angeles (UCLA) Los Angeles California
University of Southern California Keck School of Medicine Los Angeles California
University of California, San Francisco Oakland California
Stanford University Palo Alto California
University of California San Francisco (UCSF) San Francisco California
Childrens Hospital Colorado Aurora Colorado
University of Colorado Anschutz Medical Campus Aurora Colorado
Rocky Mountain Gastroenterology Littleton Colorado
UConn Health - The Carole and Ray Neag Comprehensive Cancer Center Farmington Connecticut
Yale School of Medicine New Haven Connecticut
Gastroenterology of Greater Orlando Orange City Florida
Orlando Health Orlando Florida
Emory Healthcare, Emory Clinic Atlanta Georgia
GI Care for Kids LLC Atlanta Georgia
Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois
Northwestern University, Feinberg School of Medicine Chicago Illinois
Comprehensive Gastrointestinal Health, LLC Libertyville Illinois
Endeavor Health, Skokie Campus Skokie Illinois
Kansas Gastroenterology LLC Wichita Kansas
Allergy & Asthma Specialists, P.S.C. Owensboro Kentucky
Boston Specialists, Chinatown Office Boston Massachusetts
Massachusetts General Hospital Boston Massachusetts
Boston Childrens Hospital Boston Massachusetts
Mayo Clinic Rochester Minnesota
GI Associates and Endoscopy Center Flowood Mississippi
Kansas City VA Medical Center Kansas City Missouri
Washington University in Saint Louis St Louis Missouri
Allergy Partners of N.J., P.C. Ocean City New Jersey
Steven And Alexandra Cohen Children's Medical Center Of New York Lake Success New York
Weil Cornell Medicine NYP New York New York
Icahn School of Medicine at Mount Sinai New York New York
Gastroenterology Group of Rochester LLP Rochester New York
University of North Carolina at Chapel Hill Chapel Hill North Carolina
Duke University Durham North Carolina
Atrium Health / Wake Forest University School of Medicine Winston-Salem North Carolina
Great Lakes Gastroenterology Research, LLC Mentor Ohio

+ 14 more sites — see the full list on the official registry below.

On this site

📄 Dupixent (dupilumab) drug profile →

More Regeneron Pharmaceuticals trials in the USA

A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy Active, not recruiting
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma Active, not recruiting
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US Active, not recruiting
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma Active, not recruiting
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment Enrolling by invitation

Other trials for the same condition

Trial of Partial Enteral Nutrition With Dairy Free Diet in Eosinophilic Esophagitis Recruiting
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis Active, not recruiting
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06693531 on ClinicalTrials.gov ↗ ← All trials in the USA